Immunomodulation following chemotherapy.
In the last decade, immunomodulation has emerged as a mode of therapy capable of mediating the regression of cancer in some patients. This article reviews our experience with immunomodulation following transplant and non-transplant chemotherapy. We used interferon and cyclosporine A following conventional chemotherapy in a non-transplant setting for a B16 melanoma in a murine model. This combination generated cells with MHC-unrestricted cytotoxicity. We have also used immunotherapy in the transplant setting with IL-2 activated PBSC in patients with breast cancer. Of the 28 patients treated, 20 developed GVHD and the average time to reconstitution was 12 days (comparable to a control group). This article also raises the possibility of extending immunomodulation to breast cancer patients in the nontransplant setting to induce an antitumor immune response following cytoreductive chemotherapy.
Obadina
M
M
Vincent T. Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC, USA.
Verma
U
U
Hawkins
M
M
Mazumder
A
A
D000818:Animals; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D007376:Interleukin-2; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D016572:Cyclosporine; D007372:Interferons